# Epitalon: Research Overview — Highlander Peptide > A literature summary of Epitalon (Ala-Glu-Asp-Gly), a synthetic pineal tetrapeptide studied for telomerase upregulation, melatonin synthesis, and longevity biomarkers. Covers mechanism, animal and cell data, the human evidence, and regulatory status. The AEDG tetrapeptide proposed to upregulate telomerase and normalize pineal melatonin — with a decades-long animal and cell record originating largely from one research group. ## The short version Epitalon is a four-amino-acid peptide — the sequence is Ala-Glu-Asp-Gly, often written as AEDG — synthesized from the amino-acid composition of epithalamin, a polypeptide extract of the bovine pineal gland. In cell and animal studies it is proposed to do two things: upregulate the catalytic subunit of telomerase (hTERT), extending telomere length in cultured cells [4][2], and stimulate a rate-limiting enzyme in the pineal melatonin-synthesis pathway, raising melatonin levels in rat pinealocyte culture [3]. Here is the honest part. The foundational claims come predominantly from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology, and the first independent Western replication of the telomere-lengthening result was published only in 2025 [2]. The human evidence that exists is observational, lacking randomization and placebo control [5]. A 2025 systematic review describes the physico-chemical and structural characterization of the peptide as still limited, and notes that the described mechanisms may not be the only ones operating [1]. Epitalon has no FDA, EMA, or MHRA approval for any indication. This page summarizes what was studied; it is not advice and lists no human dose. ## What it is Epitalon is the synthetic tetrapeptide H-Ala-Glu-Asp-Gly-OH — four amino acids: alanine, glutamic acid, aspartic acid, and glycine. It is also called Epithalon, Epithalone, or the AEDG peptide. Its structural derivation traces to epithalamin, a polypeptide extract of the bovine pineal gland; Epitalon was synthesized as a defined, reproducible molecule from the amino-acid composition of that extract. These two must not be conflated: epithalamin (the extract) and synthetic Epitalon (the tetrapeptide) are chemically distinct. Epitalon is a research chemical. It is not approved as a drug or dietary supplement in the US, EU, or UK, and has not cleared the safety, purity, and efficacy review that regulated medicines undergo [1]. ## How it works Two mechanisms dominate the published proposals, both originating in in vitro and animal work. *Telomere axis.* In human fetal fibroblast cultures that were initially telomerase-negative, adding the Epithalon peptide induced expression of the catalytic telomerase subunit (hTERT), enzymatic telomerase activity, and measurable telomere elongation [4]. A 2025 independent study extended this: in normal human cell lines (IBR.3 fibroblasts, HMEC) Epitalon at 0.1-1 ug/mL extended telomere length via hTERT upregulation and telomerase activation; in breast-cancer cell lines the telomere extension occurred predominantly through the Alternative Lengthening of Telomeres (ALT) pathway rather than hTERT [2]. The distinction between normal and cancer-cell mechanisms is important and unresolved at the in-human level. *Pineal melatonin axis.* In Wistar rat pinealocyte culture, the AEDG peptide stimulated the rate-limiting melatonin-synthesis enzyme AANAT and its transcription factor pCREB, and raised melatonin levels in the medium; co-administration with norepinephrine potentiated these effects [3]. This is framed as normalization of the age-related decline in melatonin output, but the translation from rat pinealocytes in culture to human circadian biology is not established. A 2025 review also discusses a proposed epigenetic component — AEDG binding to histone H1 subtypes and specific DNA motifs associated with chromatin decondensation in aged cells — while acknowledging that physico-chemical characterization of the peptide remains limited and that the described mechanisms may not be the only ones [1]. ## What the research shows *Cell-level telomere work.* The 2003 study in human fetal fibroblasts established the telomerase-induction claim [4]. The 2025 Biogerontology study by Al-Dulaimi and colleagues replicated and extended it across normal and cancer cell lines, distinguishing hTERT-dependent extension in normal cells from ALT-dependent extension in cancer lines [2]. *Pineal mechanism.* Khavinson and colleagues (2012) demonstrated AANAT and pCREB stimulation and raised melatonin output in rat pinealocyte culture [3]. *Mouse lifespan model.* In female SHR mice given Epitalon at 1.0 ug/mouse subcutaneously over five days per month from age three months, maximum lifespan increased 12.3%, leukemia incidence was reduced sixfold, and chromosome aberrations in bone marrow were lower — while total tumor incidence was unchanged and mean lifespan did not significantly differ from controls [6]. These are specific carcinogen and transgenic-adjacent cancer models, not general oncological safety surveillance. *Oocyte oxidative stress model.* At 0.1 mM in mouse oocytes, Epitalon delayed post-ovulatory aging in vitro by reducing reactive oxygen species and improving mitochondrial activity at 6, 12, and 24 hours [7]. *Human observational evidence.* In a 6-8 year observational study of 266 elderly persons in Russia, the pineal peptide Epithalamin (not synthetic Epitalon) alone was associated with a 1.6-1.8-fold decrease in mortality versus untreated controls; the combination of thymalin plus Epithalamin given annually for six years was associated with a 4.1-fold decrease [5]. The study lacked randomization and a placebo arm by Western standards, and it used the bovine extract, not the synthetic tetrapeptide. These distinctions are not cosmetic — they limit how directly the mortality numbers map onto Epitalon as a compound. ## Reported effects, cautions & safety Community reports about Epitalon circulate in longevity and biohacking forums. These are anecdotal accounts — not clinical data — and they are presented here clearly as such. **What community members report (anecdotal, not clinical evidence):** The most consistently mentioned subjective effect is better, deeper sleep and faster sleep onset, framed as more restorative nights; a subset describe a sense of normalized circadian rhythm or reduced jet-lag-like grogginess. Some report increased daytime energy and a general sense of well-being or vitality. A few note perceived cosmetic improvements — skin looking fresher, hair feeling stronger — which is subjective self-assessment with no controlled before-and-after data and a strong likelihood of expectation bias. Mild headache or lightheadedness is occasionally mentioned in the early part of a cycle. Injection-site reactions — redness, soreness, small bruising — are reported as the most common physical complaint with subcutaneous use, consistent with general self-injection rather than a specific compound effect. Transient drowsiness or vivid dreams appear in a minority of accounts. A very common outcome, and an important counterweight, is *no noticeable effect whatsoever*. Skepticism about product identity and purity — sourcing concerns — recurs in experienced community discussions. Users with quantitative longevity tracking also frequently note disappointment that the dramatic telomere-lengthening and lifespan claims rest on animal and lab work and cannot be observed or measured in themselves. **Cautions from the cited literature:** - *Not approved for human use.* Epitalon has no FDA, EMA, or MHRA approval and no registered indication; it has never cleared the safety, efficacy, and purity review that regulated medicines undergo [1]. - *Single-lineage evidence base.* Most foundational claims come from Khavinson and colleagues at the St. Petersburg Institute; the first Western independent replication of the telomere claim appeared only in 2025 [2]. Findings not yet independently reproduced may not generalize. - *Human evidence is observational only.* The cited human study (PMID 14523363) lacked randomization and a placebo arm and used a different compound (epithalamin extract, not synthetic Epitalon). Reported benefits cannot be separated from selection or expectation effects [5]. - *Theoretical telomerase-and-cancer concern.* Telomerase reactivation is a hallmark of most cancers. The 2025 Biogerontology study found Epitalon extended telomere length in breast-cancer lines through ALT activation [2], so the oncological implications of activating these pathways in humans are unresolved [1]. - *No published human pharmacokinetics.* The often-cited short half-life is inferred from short-peptide chemistry, not a measured value. No human PK/PD study of Epitalon exists. - *Anti-tumor data are from narrow experimental models.* Rodent carcinogenesis studies used specific carcinogen-exposed or transgenic cancer models, not general oncological safety surveillance [6]. ## Where it fits in longevity research Epitalon is the lead compound on this desk and the one with the more provocative claims — telomere extension, lifespan extension in mice, melatonin normalization. It is also the one where the evidence-quality caveats are most important to keep in view: single-lineage origin, observational human data using a different compound, and mechanisms (telomerase reactivation) that carry a genuine theoretical dual-use concern. The 2025 independent replication [2] represents real progress — it is the first external corroboration of the telomere claim — but it is a cell-culture result and not a clinical trial. Read alongside [NAD+](/nad), whose human RCT base is more robust even if its clinical translation is also uncertain, Epitalon illustrates where the longevity-peptide field stands: mechanistically intriguing, preclinically suggestive, and still several carefully controlled human trials short of a firm verdict. See the [comparison page](/compare) for a side-by-side view. ![Epitalon pineal gland and telomere cap research illustration](/images/epitalon.webp) --- A peer-reviewed literature digest for longevity and cellular health research — citations held to source, claims held to species.